Shots:
- Janux has entered into a collaboration & exclusive global license agreement with BMS to develop a novel, undisclosed tumor-activated therapy targeting a validated solid-tumor antigen expressed across multiple cancer types
- Janux will advance the program through preclinical development & IND submission, after which BMS will hold the IND, lead global development & commercialization, with Janux supporting through completion of the first P-I study
- As per the deal, Janux will receive ~$50M in upfront & near-term milestone payments, & ~$800M in development, regulatory & commercial milestones, with tiered royalties on global product sales
Ref: Businesswire | Image: BMS & Janux | Press Release
Related News: insitro and Bristol Myers Squibb Collaborate to Advance Drug Discovery for Amyotrophic Lateral Sclerosis (ALS)
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
